CClinicalTrials.gg
Status unknownNCT03925363Updated Jul 2, 2019

A Mobile Application to Increase Physical Activity

An interventional study of Physical activity mobile-application in Physical Activity, sponsored by Region Västerbotten. Status unknown. Open to participants aged 70 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Region Västerbotten · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
70 Years to 75 Years
Sex
All
01

Study summary

A mobile application will be tested in elderly men and women that is randomized to an application (blind-app) that registers physical activity or an application (feedback-app) where participants in addition set goals for physical activity and gets feedback from the application when these goals are achieved. Participants are randomized in permuted blocks of 10 to the blind-app or feedback-app. The primary outcome is increased physical activity. Secondary outcomes include, cardiovascular disease, diabetes, death, dementia, cancer, falls and fractures.

Read the detailed description

In this randomized controlled study, it will be tested if a mobile application can increase physical activity and reduce the risk of later non-communicable disease.

Participants include individuals that previously have been included in a health survey (Healthy aging initiative, NCT03312439), with a low registered physical activity. Low physical is defined according to WHOs definition, i.e. at least 150 minutes of physical activity per week. Individuals will diabetes will be investigated separately.

Individuals will be excluded that cannot walk for exercise, or if they have diseases that severely affects the ability to exercise. We will also seek participants from the general population to be included with only two inclusion criteria; having a smart phone and at least 18 years of age.

Participants the meet the inclusion criteria will be randomized to an application that only registers physical activity (blind-app) or an application where the participants will set appropriate goals for physical activity and get proper feedback from the app when these goals are reached (feedback-app). Both groups will have individualized information about proper physical activity. Randomization will be made using sealed envelopes in permuted blocks of 10. Randomization will be stratified on year of birth and sex.

The primary outcome will be increased physical activity after 6 months. Secondary outcomes include cardiovascular disease, death, dementia, falls and fractures, diabetes, and improved glucose control in those that already have diabetes. Secondary outcomes also include changes in cardiovascular risk factors, such as blood pressure, blood lipids and obesity. Interaction analysis will be performed to investigate if the effects are different in men and women, based on baseline physical activity and based on age.

Based on the results from the previous health survey the individuals have participated in, a power analyses has been conducted. The participants physical activity were registered using accelerometers. The mean steps taken per week was 48000 with a standard deviation of 22000 steps. With assumption that the feedback-app will increase physical activity by at least 15%, 164 individuals would be needed in each group with an alpha level of 0.05 and a power of 80%. For secondary outcome of cardiovascular disease or death, estimates were based on incidence of these outcomes in 3617 individuals that participated in the health survey. During a mean follow up time of 928 days, 221 participants was diagnosed with cardiovascular disease or died during follow up, and 128 were diagnosed with cardiovascular disease. If assuming that the mobil-application will result in 15% lower risk of these two outcomes in those randomized to the feedback-app, 597 and 1371 individuals would be needed in each group, respectively, with the same follow up time. The effects during follow up will be monitored each year of follow up through patient registers. Follow up time is scheduled to a maximum of 2 years. We estimate that we then would need 895 and 2156 individuals in each group due to the shorter follow up time compared to in the example above.

02

Conditions studied

  • Physical Activity
03

In context

Lead sponsor

Region Västerbotten is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Previous participants in healthy aging initiative.

Exclusion criteria

Exclusion Criteria:

  • Not able to walk or previous medical diagnoses that severely limits the possibility to exercise.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
4,000 participants (estimated)

Study arms

  • Active comparator
    Active

    Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)

    Device: Physical activity mobile-application

  • Sham comparator
    Control

    Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).

    Device: Physical activity mobile-application

Interventions

  • DevicePhysical activity mobile-application

    The active group will be given the feedback app and the control group the blind app

06

What researchers measure

Primary outcomes

  1. Increased physical activity as measured by the mobile application in steps per day

    Increased physical activity in steps per day during the intervention period.

    Time frame: 3 years (anticipated)

Secondary outcomes

  1. Incidence of myocardial infarction

    Diagnoses of myocardial infarction will be tracked using national registers.

    Time frame: 3 years

  2. Incidence of diagnosed diabetes

    Diabetes diagnoses or start of treatment for diabetes will be tracked using national registers.

    Time frame: 3 years

  3. Incidence of diagnosed fractures

    Diagnosed fractures will be tracked using national registers.

    Time frame: 3 years

  4. Incidence of diagnosed dementia

    Diagnosed dementia or start of treatment using dementia drugs will be tracked using national registers.

    Time frame: 3 years

  5. Number of participants with high blood pressure

    Systolic and diastolic blood pressure will be assessed at baseline and later using a sphygmomanometer.

    Time frame: 1 year (anticipated)

  6. Number of participants with high blood lipids

    Blood lipids (cholesterol, LDL-cholesterol, and triglycerides) will be analyzed at baseline and after 6 and 12 months at the department of chemistry.

    Time frame: 1 year (anticipated)

  7. Number of participants with high blood glucose

    Blood glucose will be analysed at the departement of clinical chemistry at baseline and follow up.

    Time frame: 1 year (anticipated)

  8. Grade of obesity

    Obesity will be assessed using a non-elastic measurement tape at the waist

    Time frame: 1 year (anticipated)

  9. Body weight

    Body weight in kilogram measured by a digital scale.

    Time frame: 1 year (anticipated)

  10. Incidence of stroke

    Diagnoses of stroke will be tracked using national registers.

    Time frame: 3 years

  11. Incidence of angina pectoris

    Diagnoses of angina pectoris will be tracked using national registers.

    Time frame: 3 years

  12. Incident mortality

    Death during follow up will be tracked using national registers.

    Time frame: 3 years

  13. Number of participants with high glycated hemoglobin

    Glycated hemoglobin will be measured at baseline and follow up at the Department of clinical chemistry

    Time frame: 1 year (anticipated)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03925363
Lead sponsor
Region Västerbotten
Collaborators
Umeå University
Responsible party
Anna Nordström (Associate Professor, Region Västerbotten) — Principal investigator
First posted
Apr 24, 2019
Start date
Aug 25, 2019 (estimated)
Primary completion
Jan 1, 2021 (estimated)
Completion
Jan 1, 2023 (estimated)
Last update
Jul 2, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion